Communication Oncologie

  • Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.

    Armand-Labit V, Meyer N, Casanova A, Bonnabau H, Platzer V, Tournier E, Sansas, B, Verdun S, Thouvenot B, Hilselberger B, Doncescu A, Lamant L, Lacroix-Triki M, Favre G, Pradines A. Acta derm Venereol. 2015 Jun 3.

  • RNA DNA Differences are associated with triple negative breast cancer severity

    Bernard E Bihain, Marie Brulliard, Benoit Thouvenot and Stéphane Verdun The genomics of common diseases Cambridge, 2015

  • Clinical utility of in depth RNA sequencing for non-metastatic triple negative breast cancer

    Thouvenot B, Verdun S, Tomasina J, Hilselberger B, Brulliard M, Bonnard L, Trarbach M, Roitel O, Jacquenet S, Ogier V, Bihain BE. ASCO, 2015

  • RNA DNA divergences: An unsuspected marker of cancer genomic instability accurately predicts triple-negative breast cancer severity

    Bernard E. Bihain, Stéphane Verdun, Julie Tomasina, Benoit Hilselberger, Marie Brulliard, Lionel Bonnard, Marina Trarbach, Olivier Roitel, Sandrine Jacquenet, Virginie Ogier, Jean-Pierre Armand, and Benoit Thouvenot AACR, 2015

  • Using next-generation sequencing to predict clinical outcome of triple negative breast cancer

    Thouvenot B, Verdun S, Tomasina J, Hilselberger B, Brulliard M, Bonnard L, Trarbach M, Roitel O, Jacquenet S, Armand JP, Ogier V, Bihain BE. 14TH ST.Gallen International Breast Cancer Conference, 2015

  • Prediction of triple-negative breast cancer outcome using RNA-DNA divergence rate.

    Thouvenot B, Verdun S, Tomasina J, Hilselberger B, Brulliard M, Roitel O, Jacquenet S, Ogier V, Bihain BE. AACC, 2014

  • RNA-DNA divergence rate predicts clinical outcome of triple-negative breast cancer

    Thouvenot B, Verdun S, Tomasina J, Hilselberger B, Brulliard M, Roitel O, Jacquenet S, Ogier V, Bihain BE. Munich Biomarker Conférence, 2014

  • First double validation of transcription infidelity biomarkers for breast cancer diagnosis.

    Ogier V, Brulliard M, Jacquenet S, Roitel O, Thouvenot B, Collignon O, Notet V, Gautier B, Fougere M, Maskali F, JCinqualbre J, Oudet P, Mathelin C, Durand M, Grosdidier G, Siat J, Karcher G, Armand JP, Amalric F, Bihain BE, André F, Favre G. AACR, 2011

  • Tests multiples pour la comparaison des probabilités de survenue d’une infidélité de transcription dans des ARNm sains et cancéreux.

    Collignon O, Brulliard M, Monnez JM, Vallois P, Thouvenot B, Jacquenet J, Ogier V, Roitel O and Bihain BE. 42èmes Journées de Statistique. Marseille, 2010

  • Decoding aberrant cancer mRNA: Novel path toward diagnosis and understanding non small cell lung cancer heterogeneity.

    Ogier V, Brulliard M, Thouvenot B, Battais B, Notet V, Richard C, Maskali F, Collignon O, Moncuquet P, Harter V, Sponne I, Roitel O, Durand M, Renaudin JM, Poch O, Oudet P, Beau Faller M, Plénat F, Karcher G, Delsol G, Cinqualbre J, Jacquenet J, Moro-Sibilot D, Brambilla E, Brambilla CG, Amalric F, Bihain BE. AACR, 2009

  • Increased mRNA sequence alterations in cancer as corroborated by SAGE.

    Kieffer D, Bianchetti L, Brulliard M, Collignon O, Moncuquet P, Harter V, Oudet P, Bihain B, Poch O CGE, 2008

  • Nonrandom variations in human cancer ESTs indicate that mRNA heterogeneity increases during carcinogenesis.

    Brulliard M, Lorphelin D, Collignon O, Lorphelin W, Thouvenot B, Gothié E, Jacquenet S, Ogier V, Roitel O, Monnez JM, Vallois P, Yen FT, Poch O, Guenneugues M, Karcher G, Oudet P, Bihain BE. Proc Natl Acad Sci U S A. 2007;104(18):7522-7.